TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

Go back to TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
TG THERAP (NASDAQ: TGTX) Delayed: 55.99 +0.01 (0.02%)
Previous Close $55.98    52 Week High $14.87 
Open $55.99    52 Week Low $4.90 
Day High $55.99    P/E N/A 
Day Low $55.99    EPS $-0.67 
Volume 9,872